Skip to main content
Premium Trial:

Request an Annual Quote

Strategic Diagnostics' Antibody Revenue Gains Tempered by Ag/GMO Decline

NEW YORK (GenomeWeb News) — Strategic Diagnostics today said third-quarter revenues were flat as R&D spending rose 9 percent and profit fell around 70 percent.
Total receipts for the three months ended Sept. 30 dipped slightly to $6.56 million from $6.62 million year over year.
The company said antibody revenues rose 15.2 percent over the quarter from $3.1 million to $3.6 million, and accounted for nearly 55 percent of total revenue. Strategic Diagnostics' food pathogen detection sales rose 22.6 percent to $1.1 million.
These revenue gains were offset by a nearly 50 percent drop in sales from the company's legacy US Ag/GMO business year-over-year.
Strategic Diagnostics’ R&D spending rose to $723,000 from $666,000 million year over year.
The company said third-quarter profit shrank to $100,000 from $332,000 in the year-ago period.
Strategic Diagnostics finished the quarter with around $11.9 million in cash and cash equivalents.
The company did not offer revenue predictions for full-year 2007.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.